BioSpace News Archive

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) granted marketing authorization for LORVIQUA® (lorlatinib, available in the U.S. under the brand name LORBRENA®) as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

Sun Genomics, creator of Floré, the world’s only fully customized precision probiotic, announced it is expanding its gut health test options for its Floré product line in 2022.

B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL.

Laboratoires Théa SAS, Europe’s leading independent pharmaceutical company specializing in the research, development, and commercialization of eye-care products, announced an agreement to purchase seven branded ophthalmic products from Akorn Operating Company LLC.

Eli Lilly and Company (NYSE: LLY) plans to invest over $1 billion to create a new manufacturing site, along with nearly 600 new jobs in Concord, North Carolina.

Autorefractor, also called automated refractor, is a computerized device that is used during eye tests.

Cerebral palsy refers to a group of disorders that impede a person’s ability to walk or move and maintain physical balance. One of the most common motor disabilities, cerebral palsy is a congenital disorder generally caused by abnormal brain development before birth.

ObsEva SA announced that its board of directors approved on January 28, 2022 an increase of its share capital from 85,220,471 to 108,620,471 shares through the issuance of 23,400,000 newly registered shares at an issue price of 1/13 of a Swiss Franc each.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment of D. Gordon Strickland to its Board of Directors, effective as of January 27, 2022.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to new employees.